Medical technology company Stryker announced a reduction in its 2026 sales outlook to between 6.5% and 7%, compared to previous expectations of 8.3% to 9.3%, following a noticeable slowdown in the number of hip and knee replacement surgeries in the third quarter of the year.
The company reported third-quarter revenue of $6.5 billion, a year-over-year increase of 7.7%, while net income fell to $753 million, a 12.3% year-over-year decline. Outgoing CEO Kevin Lobo emphasized that the slowdown is not due to losing market share to competitors, but is linked to broader economic pressures.
Reasons for the Surgical Slowdown
During the earnings call, Lobo explained that patients in the United States are delaying surgeries due to concerns regarding their ability to afford them, resulting from rising health insurance premiums and higher deductibles, as well as prior authorization denials from insurance companies. He noted that patients are now living with pain for longer periods before deciding to undergo surgery.
Details of the Partnership with CMR Surgical
On another note, Lobo addressed the recent $400 million investment in soft tissue robotics company CMR Surgical, under which Stryker will become the exclusive distributor of the company's robot in the U.S. market. He explained that choosing a strategic partnership rather than a full acquisition reduces development risks and costs, with potential plans for future acquisition should the robot prove commercially successful.
What This Means for Users and the Sector
This development reflects the sensitivity of the medical technology and orthopedic surgery sector to economic fluctuations and consumer purchasing power, even for necessary surgeries. It also highlights the strategies of major medical technology companies to expand into the robotic surgery sector through strategic partnerships to mitigate financial risks.